^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PD-L1 inhibitor

    Related drugs:
    19h
    Risk Factors Analysis of AKI in Patients with Primary Non-small Cell Lung Cancer Treated with PD-1/PD-L1 Inhibitor. (PubMed, Iran J Kidney Dis)
    Primary NSCLC patients with extrarenal irAEs, high levels of SCr and CRP, and low levels of eGFR have a higher risk of AKI after PD-1/PD-L1 inhibitor treatment. Establishing a predictive model with high accuracy is more conducive to early detection of high-risk patients. DOI: 10.52547/ijkd.7964.
    Retrospective data • Journal
    |
    CRP (C-reactive protein)
    1d
    Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic Sarcomas (clinicaltrials.gov)
    P1, N=32, Active, not recruiting, Memorial Sloan Kettering Cancer Center | Phase classification: P1b --> P1 | Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Jan 2024 --> Jan 2025
    Phase classification • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Bavencio (avelumab) • vimseltinib (DCC-3014)
    1d
    PIONEER: Window of Opportunity Study of Preoperative Immunotherapy With Atezolizumab in Local SCCHN (clinicaltrials.gov)
    P2, N=20, Completed, University Hospital, Essen | Recruiting --> Completed | Trial completion date: Dec 2024 --> Mar 2024
    Trial completion • Trial completion date
    |
    GZMB (Granzyme B)
    |
    Tecentriq (atezolizumab)
    2d
    ESR-22-21719: Neoadjuvant Tremelimumab and Durvalumab With Gem/Cis in Intrahepatic Cholangiocarcinoma (clinicaltrials.gov)
    P2, N=28, Recruiting, Georgetown University | Initiation date: Mar 2024 --> Jun 2024
    Trial initiation date • Combination therapy
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • Imjudo (tremelimumab)
    2d
    TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer (clinicaltrials.gov)
    P1/2, N=24, Active, not recruiting, Georgetown University | Trial completion date: Mar 2024 --> Dec 2024 | Trial primary completion date: Mar 2024 --> Dec 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    Bavencio (avelumab) • Talzenna (talazoparib)
    2d
    IMvoke010: A Study of Atezolizumab (Anti-Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov)
    P3, N=406, Terminated, Hoffmann-La Roche | Trial completion date: Jun 2027 --> Mar 2024 | Active, not recruiting --> Terminated; Decision to terminate the study as its primary endpoint of investigator-assessed event free survival (INV-EFS) was not met at its final EFS analysis. No new safety signals were identified.
    Trial completion date • Trial termination • Metastases
    |
    Tecentriq (atezolizumab)
    2d
    TRAVELER: A Study to Learn About the Effect of Avelumab First-Line Maintenance in Canadian People With Advanced Bladder Cancer (clinicaltrials.gov)
    P=N/A, N=150, Terminated, Pfizer | Trial completion date: Oct 2023 --> Jun 2023 | Not yet recruiting --> Terminated | Trial primary completion date: Oct 2023 --> Jun 2023; The trial was terminated for strategic reasons. The decision was not based on any safety and/or efficacy concerns.
    Trial completion date • Trial termination • Trial primary completion date • Metastases
    |
    Bavencio (avelumab)
    2d
    Durvalumab impacts progression-free survival while high-dose radiation >66 Gy improves local control without excess toxicity in unresectable NSCLC stage III: Real-world data from the Austrian radio-oncological lung cancer study association registry (ALLSTAR). (PubMed, Radiother Oncol)
    While Durvalumab impacts PFS, LC can be improved by total radiation doses > 66 Gy without excess toxicity.
    Journal • Real-world evidence • Real-world
    |
    PD-L1 (Programmed death ligand 1)
    |
    Imfinzi (durvalumab)
    2d
    Inflammatory pathways confer resistance to chemoradiotherapy in anal squamous cell carcinoma. (PubMed, NPJ Precis Oncol)
    Inflammatory pathways in tissue in line with elevated levels of regulatory T-cells and CXCL2 in peripheral blood are associated with resistance to CRT. To counteract this resistance mechanism, the RADIANCE randomized phase-2 trial currently tests the addition of the immune checkpoint inhibitor durvalumab to standard CRT in locally advanced ASCC.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CD4 (CD4 Molecule) • IFNA1 (Interferon Alpha 1)
    |
    PD-L1 expression • CD4 expression
    |
    Imfinzi (durvalumab)
    2d
    Prognostic biomarker TPM4 acts as a potential predictor of PD-1/PD-L1 inhibitor response in glioblastoma. (PubMed, Asian J Surg)
    No abstract available
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    TPM4 (Tropomyosin 4)
    2d
    BEGONIA: A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer (clinicaltrials.gov)
    P1/2, N=240, Recruiting, AstraZeneca | Trial completion date: Aug 2024 --> Nov 2024 | Trial primary completion date: Aug 2024 --> Nov 2024
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • HER-2 expression • PD-L1 expression + HER-2 overexpression
    |
    Imfinzi (durvalumab) • paclitaxel • Enhertu (fam-trastuzumab deruxtecan-nxki) • Truqap (capivasertib) • datopotamab deruxtecan (DS-1062a) • oleclumab (MEDI9447)
    3d
    Soluble programmed death ligand 1 as prognostic biomarker in non-small cell lung cancer patients receiving nivolumab, pembrolizumab or atezolizumab therapy. (PubMed, Sci Rep)
    In conclusion, sPD-L1 measured in baseline serum samples may be associated with OS in NSCLC patients receiving anti-PD1/anti-PD-L1 treatment. Importantly, the results signify that further research is warranted to explore the clinical utility of sPD-L1 in patients treated with anti-PD-L1.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab)
    3d
    ATEZOLACC: Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab (clinicaltrials.gov)
    P2, N=189, Active, not recruiting, Gustave Roussy, Cancer Campus, Grand Paris | Recruiting --> Active, not recruiting | Trial completion date: Jul 2024 --> Apr 2025 | Trial primary completion date: Jul 2024 --> Feb 2024
    Enrollment closed • Trial completion date • Trial primary completion date • Metastases
    |
    cisplatin • Tecentriq (atezolizumab)
    3d
    Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer (clinicaltrials.gov)
    P2, N=40, Recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    cisplatin • gemcitabine • AiTan (rivoceranib) • adebrelimab (SHR-1316)
    3d
    BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma (clinicaltrials.gov)
    P3, N=401, Active, not recruiting, ETOP IBCSG Partners Foundation | Trial completion date: Jan 2024 --> Jun 2024 | Trial primary completion date: Jan 2024 --> Jun 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • pemetrexed
    4d
    IOSI-LUNG-001: Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC (clinicaltrials.gov)
    P2, N=12, Active, not recruiting, Oncology Institute of Southern Switzerland | Recruiting --> Active, not recruiting | N=20 --> 12 | Trial completion date: Dec 2022 --> Dec 2024
    Enrollment closed • Enrollment change • Trial completion date • Metastases
    |
    ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    ALK fusion • ROS1 rearrangement
    |
    Tecentriq (atezolizumab)
    4d
    SADDRIN-1: Sarcomas and DDR-Inhibition; a Combined Modality Study (clinicaltrials.gov)
    P1, N=30, Recruiting, The Netherlands Cancer Institute | N=15 --> 30 | Trial completion date: Mar 2024 --> Jul 2028 | Trial primary completion date: Mar 2024 --> Mar 2026
    Enrollment change • Trial completion date • Trial primary completion date
    |
    Imfinzi (durvalumab) • AZD1390
    4d
    Study of INCB086550 in Select Solid Tumors (clinicaltrials.gov)
    P2, N=16, Terminated, Incyte Corporation | Trial completion date: Aug 2024 --> Mar 2024 | Active, not recruiting --> Terminated; Strategic business decision to terminate the study effective immediately. This is due to a company decision to prioritize another oral PD-L1 inhibitor with a more favorable profile.
    Trial completion date • Trial termination • Checkpoint inhibition
    |
    INCB86550
    4d
    Abequolixron (RGX-104) and Durvalumab in Lung Cancer (clinicaltrials.gov)
    P1, N=24, Recruiting, UNC Lineberger Comprehensive Cancer Center | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    carboplatin • Imfinzi (durvalumab) • albumin-bound paclitaxel • pemetrexed • abequolixron (RGX-104)
    4d
    IMvigor011: A Study of Atezolizumab Versus Placebo as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Bladder Cancer Who Are ctDNA Positive Following Cystectomy (clinicaltrials.gov)
    P3, N=800, Recruiting, Hoffmann-La Roche | N=520 --> 800
    Enrollment change • Circulating tumor DNA
    |
    PD-L1 expression
    |
    Tecentriq (atezolizumab)
    4d
    FRAIL-IMMUNE (GORTEC 2018-03) - Combination of Durvalumab With Carboplatin/Paclitaxel (clinicaltrials.gov)
    P2, N=104, Completed, Centre Leon Berard | Recruiting --> Completed | Trial completion date: Aug 2024 --> Mar 2024
    Trial completion • Trial completion date • IO biomarker • Metastases
    |
    CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • CD38 (CD38 Molecule) • CD4 (CD4 Molecule) • FOXP3 (Forkhead Box P3)
    |
    PD-L1 expression
    |
    carboplatin • Imfinzi (durvalumab) • paclitaxel
    4d
    Effect of Sex on the Oncological Outcomes in Response to Immunotherapy and Antibody-drug Conjugates in Patients with Urothelial and Kidney Cancer: A Systematic Review and a Network Meta-analysis. (PubMed, Eur Urol Oncol)
    The NMA revealed gender-specific variations in ICI and ADC responses for RCC and TCC, offering insights for personalised cancer care and addressing disparities in cancer care and outcomes.
    Retrospective data • Review • Journal
    |
    NECTIN4 (Nectin Cell Adhesion Molecule 4)
    |
    Tecentriq (atezolizumab)
    6d
    Real-world treatment patterns and clinical outcomes in patients with stage III NSCLC in Korea: The KINDLE study. (PubMed, Cancer Med)
    This study revealed the heterogeneity of treatment patterns and survival outcomes in patients with stage III NSCLC before durvalumab consolidation came into clinical practice. There is an unmet need for patients who are not eligible for surgery as an initial therapy. Novel therapeutic approaches are highly warranted to improve clinical outcomes.
    Clinical data • Journal • HEOR • Real-world evidence • PD(L)-1 Biomarker • IO biomarker • Real-world
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression • EGFR mutation
    |
    Imfinzi (durvalumab)
    7d
    Recent Advances in Systemic Therapy for Advanced Intrahepatic Cholangiocarcinoma. (PubMed, Liver Cancer)
    The addition of durvalumab to a gemcitabine plus cisplatin regimen has significantly improved overall survival in the phase 3 TOPAZ-1 trial and is currently recommended as a standard first-line treatment. The phase 3 ABC-06 and phase 2b NIFTY trials have shown the benefit of second-line fluoropyrimidine plus oxaliplatin, and fluoropyrimidine plus nanoliposomal irinotecan, respectively...However, most patients eventually show resistance to the treatment, and tumor progression occurs within a year. Indeed, there should be further efforts to improve the outcomes of patients with advanced IHCCA.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • FGFR2 (Fibroblast growth factor receptor 2) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    BRAF mutation • HER-2 amplification • HER-2 mutation • IDH1 mutation • FGFR2 mutation • FGFR2 rearrangement
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • oxaliplatin • Onivyde (nanoliposomal irinotecan)
    7d
    Neoadjuvant CCRT With Gemcitabine/Durvalumab (MEDI4736) Followed by Adjuvant Gemcitabine/Durvalumab(MEDI4736) in Resectable or Borderline Resectable Pancreatic Cancer (clinicaltrials.gov)
    P2, N=71, Active, not recruiting, Do-Youn Oh | Recruiting --> Active, not recruiting | Trial completion date: Nov 2021 --> Dec 2024 | Trial primary completion date: Nov 2021 --> Dec 2024
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    Imfinzi (durvalumab) • gemcitabine
    7d
    A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors (clinicaltrials.gov)
    P1, N=215, Active, not recruiting, Eli Lilly and Company | Trial completion date: Mar 2024 --> Jul 2024
    Trial completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • MSI (Microsatellite instability)
    |
    MSI-H/dMMR • HER-2 overexpression • HER-2 negative
    |
    Verzenio (abemaciclib) • Cyramza (ramucirumab) • merestinib (LY2801653) • lodapolimab (LY3300054) • LY3321367
    7d
    A Single Arm, Single Centered Phase II Trial on the Combination of Adebrelimab, Surufatinib and Irinotecan Liposome-based HAIC in Advanced iCC (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial • Metastases
    |
    Sulanda (surufatinib) • adebrelimab (SHR-1316)
    7d
    PM-CARE: Precision Medicine in Patients With Unresectable CholAngiocarcinoma: RadioEmbolization and Combined Biological Therapy (clinicaltrials.gov)
    P2, N=33, Not yet recruiting, Francesco De Cobelli
    New P2 trial • Combination therapy
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine
    7d
    ESR-15-11655: Biomarker-oriented Study of Durvalumab (MEDI4736) in Combination With Olaparib and Paclitaxel in Gastric Cancer (clinicaltrials.gov)
    P2, N=40, Active, not recruiting, Do-Youn Oh | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date • Combination therapy
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • paclitaxel
    7d
    DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer (clinicaltrials.gov)
    P2, N=74, Active, not recruiting, Seoul National University Hospital | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial primary completion date • Metastases
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • ceralasertib (AZD6738)
    7d
    AZD6738 Plus Durvalumab in Biliary Tract Cancer (clinicaltrials.gov)
    P2, N=26, Recruiting, Seoul National University Hospital | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
    Trial completion date • Trial primary completion date
    |
    Imfinzi (durvalumab) • ceralasertib (AZD6738)
    7d
    Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=10, Active, not recruiting, Rachel Sanborn | Trial completion date: Nov 2023 --> Dec 2024 | Trial primary completion date: Oct 2023 --> Jun 2023
    Trial completion date • Trial primary completion date
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • pemetrexed • etoposide IV
    7d
    Durvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naïve Biliary Tract Cancer (clinicaltrials.gov)
    P2, N=31, Active, not recruiting, Seoul National University Hospital | Trial completion date: Dec 2023 --> Dec 2024
    Trial completion date • Combination therapy
    |
    cisplatin • Imfinzi (durvalumab) • gemcitabine • Imjudo (tremelimumab)
    7d
    Development and validation of ELISA method for quantification of Q-1802 in serum and its application to pharmacokinetic study in ICR Mouse. (PubMed, J Pharm Biomed Anal)
    In conclusion, we have developed and validated a highly sensitive and selective method for measuring Q-1802 in ICR mouse serum. The development and validation steps of assays met the required criteria for validation, which suggested that these can be applied to quantify Q-1802, as well as in PK studies.
    PK/PD data • Preclinical • Journal
    |
    CLDN18 (Claudin 18)
    |
    Q-1802
    8d
    A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers (clinicaltrials.gov)
    P1/2, N=107, Recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2024 --> Dec 2025
    Trial completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
    |
    PD-L1 negative
    |
    Jingzhuda (entinostat) • bintrafusp alfa (M7824) • PDS01ADC
    8d
    BAT7104 in Patients With Advanced Solid Tumours (clinicaltrials.gov)
    P1, N=29, Active, not recruiting, Bio-Thera Solutions | Trial primary completion date: Jan 2024 --> Sep 2024
    Trial primary completion date • Metastases
    8d
    A Study to Evaluate the Efficacy and Safety of Bintrafusp Alfa (M7824) Monotherapy in Metastatic or Locally Advanced Urothelial Cancer (clinicaltrials.gov)
    P1, N=25, Terminated, GlaxoSmithKline | Active, not recruiting --> Terminated; Primary investigator withdrew the participant due to an SAE
    Trial termination • Metastases
    |
    bintrafusp alfa (M7824)
    9d
    IMperator: A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors With Resectable Disease With Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H) (clinicaltrials.gov)
    P2, N=40, Recruiting, Hoffmann-La Roche | Not yet recruiting --> Recruiting
    Enrollment open • Tumor mutational burden
    |
    Tecentriq (atezolizumab) • tiragolumab (RG6058)
    9d
    Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1) (clinicaltrials.gov)
    P1/2, N=53, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting | N=113 --> 53
    Enrollment closed • Enrollment change
    |
    TMB (Tumor Mutational Burden) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • MSI (Microsatellite instability) • HRD (Homologous Recombination Deficiency)
    |
    TMB-H • MSI-H/dMMR
    |
    bintrafusp alfa (M7824) • epacadostat (INCB024360) • Anktiva (nogapendekin alfa inbakicept-pmln)
    9d
    The Efficacy and Safety of PD-1/PD-L1 Inhibitors Combined With Centipeda Minima (CM) in Lung Cancer (clinicaltrials.gov)
    P1, N=8, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Not yet recruiting --> Recruiting | Trial completion date: Feb 2025 --> Dec 2025 | Trial primary completion date: Feb 2024 --> Aug 2025
    Enrollment open • Trial completion date • Trial primary completion date
    9d
    IBFIC: Imaging Biomarkers for Immune Checkpoint Inhibitor Treatment in Patients With Non-small Cell Lung Cancer (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, Samsung Medical Center | Trial primary completion date: Dec 2023 --> Dec 2025
    Trial primary completion date • Checkpoint inhibition • IO biomarker
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab)
    9d
    Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC (clinicaltrials.gov)
    P3, N=48, Recruiting, Maximilian Diehn | Trial completion date: Mar 2026 --> Apr 2028 | Trial primary completion date: Mar 2024 --> Apr 2026
    Trial completion date • Trial primary completion date
    |
    cisplatin • carboplatin • Imfinzi (durvalumab) • paclitaxel • Imjudo (tremelimumab) • pemetrexed